Skip to main content
JINLING PHARMACEUTICAL CO.,LTD logo

JINLING PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 000919 ISIN · CNE0000010W5 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,771 across all filing types
Latest filing 2020-05-05 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 000919

About JINLING PHARMACEUTICAL CO.,LTD

https://www.jlyy1999.com

Jinling Pharmaceutical Co., Ltd. specializes in the research, development, manufacture, and sale of pharmaceutical products, with a focus on chemical drugs and traditional Chinese medicine preparations. The company’s product portfolio primarily targets cardiovascular and cerebrovascular diseases, anti-tumor treatments, and digestive system health. A prominent product in its lineup is the Mailuoning Injection, utilized for treating various vascular conditions. In addition to its manufacturing operations, the company is involved in the management and operation of medical institutions, integrating clinical services with pharmaceutical production. Its business model emphasizes the synergy between drug development and healthcare service delivery to provide integrated medical solutions.

Recent filings

Filing Released Lang Actions
关于设立全资子公司进展情况的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Jinling Pharmaceutical Co., Ltd. regarding the progress of establishing a wholly-owned subsidiary. It details the board resolution approving the investment, the registration of the new subsidiary, and its business scope. There are no financial statements, audit information, or detailed financial data. The document is a corporate announcement about a capital investment and subsidiary formation, which fits best under Capital/Financing Update (CAP). The document length is short and it is not a report publication announcement or regulatory filing. Therefore, the classification is CAP with high confidence.
2020-05-05 Chinese
2020年第一季度报告全文
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2020 First Quarter Report" of 金陵药业股份有限公司, indicating it is a quarterly financial report. It contains detailed financial data such as revenue, net profit, cash flow, earnings per share, and asset information for the quarter ending in 2020 Q1. It also includes shareholder information and notes on significant financial changes and commitments. The length is substantial (15,000 characters) and contains actual financial statements and analysis, not just an announcement or summary. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q1 2020
2020-04-27 Chinese
2020年第一季度报告正文
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2020 First Quarter Report" of Jinling Pharmaceutical Co., Ltd. It contains detailed financial data for the first quarter of 2020, including revenue, net profit, earnings per share, cash flow, and asset information. It also includes shareholder information and explanations of financial changes during the reporting period. The presence of comprehensive financial statements and analysis for a period shorter than a full fiscal year indicates this is an Interim / Quarterly Report. The document length is substantial (15,000 characters), and it contains actual financial data, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2020
2020-04-27 Chinese
2020年第一季度业绩预告
Earnings Release Classification · 95% confidence The document is a quarterly earnings forecast for the first quarter of 2020 by Jinling Pharmaceutical Co., Ltd. It provides estimated financial performance figures, including net profit and earnings per share, and explains reasons for the expected decline in profits. It explicitly states that the forecast is unaudited and preliminary, and that the final audited financial data will be disclosed in the formal quarterly report. The document is not the full quarterly report itself but a performance forecast announcement. Given the content and length (1736 characters), it fits the category of an Earnings Release (ER), which is the initial announcement of quarterly financial results or forecasts with key highlights only. Q1 2020
2020-04-13 Chinese
2019年年度报告摘要
Annual Report Classification · 100% confidence The document is titled as the "2019 Annual Report Summary" of Jinling Pharmaceutical Co., Ltd. It contains detailed financial data for the year 2019, including revenue, net profit, earnings per share, and asset information. It also discusses business operations, industry environment, management commentary, and shareholder information. The length is substantial (15,000 characters), and the content is comprehensive, covering the company's full-year financial performance and business overview. This matches the characteristics of an Annual Report (10-K) rather than a brief announcement or a regulatory filing. Therefore, the document is classified as an Annual Report (10-K). FY 2019
2020-03-30 Chinese
独立董事2019年度述职报告（冯巧根）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director 2019 Annual Report" and contains a detailed narrative of the independent director's duties, attendance at board meetings, opinions expressed, committee work, and efforts to protect shareholder rights during the 2019 fiscal year. It is a formal report by an independent director summarizing their activities and responsibilities over the year. The content is not a general annual report of the company, nor is it an announcement or a brief notice. It is a management-related report focusing on governance and oversight activities by an independent director. This fits best under the category of Board/Management Information (MANG), which includes announcements or reports related to board members and senior management activities. The document length is 2077 characters, which is relatively short but contains substantive content about the independent director's role and activities, not just an announcement or certification. Therefore, the classification is MANG with high confidence.
2020-03-30 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.